(DHR) Danaher - Ratings and Ratios
Biotechnology, Life Sciences, Diagnostics, Medical Equipment, Research Tools
DHR EPS (Earnings per Share)
DHR Revenue
Description: DHR Danaher
Danaher Corporation is a diversified healthcare and life sciences company that operates through three main segments: Biotechnology, Life Sciences, and Diagnostics. The company offers a wide range of products and services, including bioprocessing technologies, mass spectrometers, clinical instruments, and genomic medicines, under various brands such as Beckman Coulter, Leica Microsystems, and IDT.
From a business perspective, Danahers diverse portfolio and strong brand presence enable it to capitalize on growth opportunities in the life sciences and diagnostics markets. The companys focus on innovation and R&D is evident in its partnerships, such as the one with AstraZeneca PLC, to develop and commercialize diagnostic tools and tests. Key performance indicators (KPIs) to watch include revenue growth, segment-wise profitability, and return on invested capital (ROIC). With a strong track record of acquisitions and integration, Danahers ability to generate cash flows and maintain a healthy balance sheet is crucial.
In terms of financial metrics, Danahers market capitalization stands at approximately $145 billion, with a forward P/E ratio of 26.81, indicating a relatively high valuation. To justify this valuation, the company needs to demonstrate sustained earnings growth and expansion in its key segments. Other important KPIs include operating margin expansion, working capital management, and dividend yield. With a history of strong cash generation, Danahers ability to return capital to shareholders through dividends and share buybacks is also worth monitoring.
To further analyze Danahers prospects, its essential to examine its segment-wise performance, competitive positioning, and innovation pipeline. The Biotechnology segments growth prospects, driven by increasing demand for bioprocessing technologies, are particularly noteworthy. Similarly, the Diagnostics segments ability to capitalize on the growing demand for clinical diagnostics and testing is crucial. By monitoring these KPIs and segment-wise performance, investors can gain a deeper understanding of Danahers growth prospects and potential risks.
DHR Stock Overview
| Market Cap in USD | 150,528m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1979-01-05 |
DHR Stock Ratings
| Growth Rating | -27.5% |
| Fundamental | 48.0% |
| Dividend Rating | 58.3% |
| Return 12m vs S&P 500 | -34.1% |
| Analyst Rating | 4.62 of 5 |
DHR Dividends
| Dividend Yield 12m | 0.57% |
| Yield on Cost 5y | 0.66% |
| Annual Growth 5y | 11.10% |
| Payout Consistency | 92.7% |
| Payout Ratio | 15.7% |
DHR Growth Ratios
| Growth Correlation 3m | 56.7% |
| Growth Correlation 12m | -82.9% |
| Growth Correlation 5y | 3.1% |
| CAGR 5y | 2.75% |
| CAGR/Max DD 5y | 0.07 |
| Sharpe Ratio 12m | 0.60 |
| Alpha | -36.57 |
| Beta | 0.714 |
| Volatility | 29.30% |
| Current Volume | 2519.8k |
| Average Volume 20d | 3176.9k |
| Stop Loss | 199.1 (-3%) |
| Signal | 1.05 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (3.41b TTM) > 0 and > 6% of Revenue (6% = 1.44b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.52% (prev 12.34%; Δ 5.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 6.17b > Net Income 3.41b (YES >=105%, WARN >=100%) |
| Net Debt (15.60b) to EBITDA (6.75b) ratio: 2.31 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (719.1m) change vs 12m ago -3.14% (target <= -2.0% for YES) |
| Gross Margin 61.52% (prev 59.27%; Δ 2.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 29.98% (prev 30.00%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.01 (EBITDA TTM 6.75b / Interest Expense TTM 291.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.11
| (A) 0.05 = (Total Current Assets 11.00b - Total Current Liabilities 6.79b) / Total Assets 81.62b |
| (B) 0.55 = Retained Earnings (Balance) 45.24b / Total Assets 81.62b |
| (C) 0.05 = EBIT TTM 4.37b / Avg Total Assets 80.09b |
| (D) 1.53 = Book Value of Equity 44.68b / Total Liabilities 29.28b |
| Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.03
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 2.93% = 1.46 |
| 3. FCF Margin 20.25% = 5.06 |
| 4. Debt/Equity 0.35 = 2.44 |
| 5. Debt/Ebitda 2.75 = -1.38 |
| 6. ROIC - WACC -2.33% = -2.92 |
| 7. RoE 6.69% = 0.56 |
| 8. Rev. Trend -62.18% = -3.11 |
| 9. Rev. CAGR -8.87% = -1.48 |
| 10. EPS Trend -84.11% = -2.10 |
| 11. EPS CAGR -30.89% = -2.50 |
What is the price of DHR shares?
Over the past week, the price has changed by +0.68%, over one month by +1.16%, over three months by +8.79% and over the past year by -22.43%.
Is Danaher a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DHR is around 179.80 USD . This means that DHR is currently overvalued and has a potential downside of -12.42%.
Is DHR a buy, sell or hold?
- Strong Buy: 19
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 246 | 19.8% |
| Analysts Target Price | 247.1 | 20.4% |
| ValueRay Target Price | 199.1 | -3% |
Last update: 2025-08-15 15:21
DHR Fundamental Data Overview
CCE Cash And Equivalents = 2.96b USD (last quarter)
P/E Trailing = 44.6327
P/E Forward = 27.7778
P/S = 6.2686
P/B = 2.8763
P/EG = 2.1049
Beta = 0.761
Revenue TTM = 24.01b USD
EBIT TTM = 4.37b USD
EBITDA TTM = 6.75b USD
Long Term Debt = 16.85b USD (from longTermDebt, last quarter)
Short Term Debt = 1.70b USD (from shortTermDebt, last quarter)
Debt = 18.55b USD (Calculated: Short Term 1.70b + Long Term 16.85b)
Net Debt = 15.60b USD (from netDebt column, last quarter)
Enterprise Value = 166.13b USD (150.53b + Debt 18.55b - CCE 2.96b)
Interest Coverage Ratio = 15.01 (Ebit TTM 4.37b / Interest Expense TTM 291.0m)
FCF Yield = 2.93% (FCF TTM 4.86b / Enterprise Value 166.13b)
FCF Margin = 20.25% (FCF TTM 4.86b / Revenue TTM 24.01b)
Net Margin = 14.21% (Net Income TTM 3.41b / Revenue TTM 24.01b)
Gross Margin = 61.52% ((Revenue TTM 24.01b - Cost of Revenue TTM 9.24b) / Revenue TTM)
Tobins Q-Ratio = 3.72 (Enterprise Value 166.13b / Book Value Of Equity 44.68b)
Interest Expense / Debt = 0.38% (Interest Expense 71.0m / Debt 18.55b)
Taxrate = 16.08% (from yearly Income Tax Expense: 747.0m / 4.65b)
NOPAT = 3.66b (EBIT 4.37b * (1 - 16.08%))
Current Ratio = 1.62 (Total Current Assets 11.00b / Total Current Liabilities 6.79b)
Debt / Equity = 0.35 (Debt 18.55b / last Quarter total Stockholder Equity 52.33b)
Debt / EBITDA = 2.75 (Net Debt 15.60b / EBITDA 6.75b)
Debt / FCF = 3.82 (Debt 18.55b / FCF TTM 4.86b)
Total Stockholder Equity = 51.01b (last 4 quarters mean)
RoA = 4.18% (Net Income 3.41b, Total Assets 81.62b )
RoE = 6.69% (Net Income TTM 3.41b / Total Stockholder Equity 51.01b)
RoCE = 6.44% (Ebit 4.37b / (Equity 51.01b + L.T.Debt 16.85b))
RoIC = 5.40% (NOPAT 3.66b / Invested Capital 67.85b)
WACC = 7.74% (E(150.53b)/V(169.08b) * Re(8.65%)) + (D(18.55b)/V(169.08b) * Rd(0.38%) * (1-Tc(0.16)))
Shares Correlation 5-Years: -60.0 | Cagr: -0.66%
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.27% ; FCFE base≈4.96b ; Y1≈4.71b ; Y5≈4.51b
Fair Price DCF = 100.7 (DCF Value 72.10b / Shares Outstanding 716.1m; 5y FCF grow -6.55% → 3.0% )
Revenue Correlation: -62.18 | Revenue CAGR: -8.87%
Rev Growth-of-Growth: 15.52
EPS Correlation: -84.11 | EPS CAGR: -30.89%
EPS Growth-of-Growth: 14.69
Additional Sources for DHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle